Elucidation of the anti-β-cell dedifferentiation mechanism of a modified Da Chaihu Decoction by an integrative approach of network pharmacology and experimental verification
Journal of Ethnopharmacology · 2024
DOI: 10.1016/j.jep.2023.117481 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Ethnopharmacology, 2024. Verfasst von Hongdong Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Beijng Hepingli Hospital, NO.18th Hepingli North Street, Beijing, 100013, China; Renal Research Institution of Beijing U…. Hauptthemen laut MEDLINE: Insulin-Secreting Cells, Diabetes Mellitus, Type 2, Insulin Resistance, Diabetes Mellitus, Experimental. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
ETHNOPHARMACOLOGICAL RELEVANCE: Modified Da Chaihu decoction (MDCH) is a traditional Chinese herbal prescription that has been used in the clinic to treat type 2 diabetes (T2D). Previous studies have confirmed that MDCH improves glycemic and lipid metabolism, enhances pancreatic function, and alleviates insulin resistance in patients with T2D and diabetic rats. Evidence has demonstrated that MDCH protects pancreatic β cells via regulating the gene expression of sirtuin 1 (SIRT1) and forkhead box protein O1 (FOXO1). However, the detailed mechanism remains unclear. AIM OF THE STUDY: Dedifferentiation of pancreatic β cells mediated by FOXO1 has been recognized as the main pathogenesis of T2D. This study aims to investigate the therapeutic effects of MDCH on T2D in vitro and in vivo to elucidate the potential molecular mechanisms. MATERIALS AND METHODS: To predict the key targets of MDCH in treating T2D, network pharmacology methods were used. A T2D model was induced in diet-induced obese (DIO) C57BL/6 mice with a single intraperitoneal injection of streptozotocin. Glucose metabolism indicators (oral glucose tolerance test, insulin tolerance test), lipid metabolism indicators (total cholesterol, triglyceride, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol), inflammatory factors (C-reactive protein, interleukin 6, tumor necrosis factor alpha), oxidative stress indicators (total antioxidant capacity, superoxide dismutase, malondialdehyde), and hematoxylin and eosin staining were analyzed to evaluate the therapeutic effect of MDCH on T2D. Immunofluorescence staining and quantification of FOXO1, pancreatic and duodenal homeobox 1 (PDX1), NK6 homeobox 1 (NKX6.1), octamer-binding protein 4 (OCT4), neurogenin 3 (Ngn3), insulin, and SIRT1, and Western blot analysis of insulin, SIRT1, and FOXO1 were performed to investigate the mechanism by which MDCH inhibited pancreatic β-cell dedifferentiation. RESULTS: The chemical ingredients identified in MDCH were predicted to be important for signaling pathways related to lipid metabolism and insulin resistance, including lipids in atherosclerosis, the advanced glycation end product receptor of the advanced glycation end product signaling pathway, and the FOXO signaling pathway. Experimental studies showed that MDCH improved glucose and lipid metabolism in T2D mice, alleviated inflammation and oxidative stress damage, and reduced pancreatic pathological damage. Furthermore, MDCH upregulated the expression levels of SIRT1, FOXO1, PDX1, and NKX6.1, while downregulating the expression levels of OCT4 and Ngn3, which indicated that MDCH inhibited pancreatic dedifferentiation of β cells. CONCLUSIONS: MDCH has therapeutic effects on T2D, through regulating the SIRT1/FOXO1 signaling pathway to inhibit pancreatic β-cell dedifferentiation, which has not been reported previously.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Beijng Hepingli Hospital, NO.18th Hepingli North Street, Beijing, 100013, China; Renal Research Institution of Beijing University of Chinese Medicine, and Key Laboratory of Chinese Internal…
- Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China; Renal Research Institution of Beijing University of Chinese Medicine, and Key Laboratory of Chinese In…
- Renal Research Institution of Beijing University of Chinese Medicine, and Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital Affiliated to Beijing University of Chinese…
- Department of Endocrinology, Beijng Hepingli Hospital, NO.18th Hepingli North Street, Beijing, 100013, China.
- Department of Endocrinology, Beijng Hepingli Hospital, NO.18th Hepingli North Street, Beijing, 100013, China. Electronic address: Hzc188@126.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Chen, H., Guo, J., Cai, Y., Zhang, C., Wei, F., Sun, H., Cheng, C., Liu, W., & He, Z. (2024). Elucidation of the anti-β-cell dedifferentiation mechanism of a modified Da Chaihu Decoction by an integrative approach of network pharmacology and experimental verification. Journal of Ethnopharmacology. https://doi.org/10.1016/j.jep.2023.117481
Vancouver
Chen H, Guo J, Cai Y, Zhang C, Wei F, Sun H, et al. Elucidation of the anti-β-cell dedifferentiation mechanism of a modified Da Chaihu Decoction by an integrative approach of network pharmacology and experimental verification. Journal of Ethnopharmacology. 2024. doi:10.1016/j.jep.2023.117481
BibTeX
@article{Chen2024,
author = {Chen, Hongdong and Guo, Jing and Cai, Yuzi and Zhang, Chao and Wei, Fudong and Sun, Hao and Cheng, Cheng and Liu, Weijing and He, Zhongchen},
title = {Elucidation of the anti-β-cell dedifferentiation mechanism of a modified Da Chaihu Decoction by an integrative approach of network pharmacology and experimental verification},
journal = {Journal of Ethnopharmacology},
year = {2024},
doi = {10.1016/j.jep.2023.117481}
}
EUVIMED